📑Dodavky leku - TOCILIZUMAB Inf 2022
Procurement process summary
This process is to purchase Dodavky leku - TOCILIZUMAB Inf 2022.
This contract was awarded by 🇨🇿 Revmatologický ústav for an amount of CZK 6,988,000 to 1 supplier. It was published on 2022-06-21 through open
Transparency in this process is reflected in the detailed publication of all aspects of the contract and its results.
Buying entity🇨🇿 Revmatologický ústav Buying unitnot reported Publication date2022-06-21 Contest statusnot reported DescriptionPredmetem plneni jsou prubezne dodavky leciveho pripravku TOCILIZUMAB_L04AC07, a to v souladu se zadavacimi podminkami.Awards
This award was granted to Roche s.r.o. by Revmatologický ústav for an amount of CZK 6,988,000. The procurement process was conducted through open for the category of goods. The award was granted on 2022-05-20. This is award number 1.
| Supplier | Amount | Award date | Award number |
|---|---|---|---|
| 🇨🇿 Roche s.r.o. | CZK 6,988,000 | 2022-05-20 | 1 |
Market context and opportunities
The execution of this contract allows the entity Revmatologický ústav to fulfill its public service objectives efficiently.
The open purchase modality ensures that the process is transparent and compliant with regulations.
Transparency in this process is reflected in the detailed publication of all aspects of the contract and its results.
This transparency in public procurement promotes fair competition, prevents corruption, and ensures that public resources are used efficiently for the benefit of citizens.
Additional data
Contract NumberCZ_ocds-70d2nz-3556d7af-0678-4971-b43e-2510cecf38fd-award-1Publication date2022-06-21Contract datenot reportedAward date2022-05-20CategoriesgoodsPurchase modalityopenMethod detailspt_openStatusnot reportedData sources
Sociedad.info publishes data from official sources, in compliance with public information access laws. Public access to this data is a civic right that helps hold government accountable. This data, including names and identifiers, is already public in the official source. Read our privacy policy.
